Catherine A. Sohn, a director at Altimmune, Inc. (NASDAQ:ALT), purchased 500 shares, boosting her total ownership to 1,500 shares.The FDA granted Breakthrough Therapy Designation to Altimmune's pemvidutide, signaling potential for substantial improvement over existing therapies for serious liver diseases.Altimmune reported robust 48-week Phase IIb data for pemvidutide, with plans for a Phase III trial aimed at accelerated approval.On January 5, 2026, Catherine A. Sohn, a director at Altimmune, Inc. (NASDAQ: ...